Rick Martin and E. David Crawford, MD, presented “Advances in COVID-19 Testing: PCR Test Validated for Sputum and Swabs” for the Grand Rounds in Urology audience in March, 2020.
How to cite: Martin, Rick. Crawford, E. David. “Advances in COVID-19 Testing: PCR Test Validated for Sputum and Swabs” March, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/advances-in-covid-19-testing-pcr-test-validated-for-sputum-and-swabs/
Advances in COVID-19 Testing: PCR Test Validated for Sputum and Swabs – Summary:
Rick Martin, CEO of MicroGen Diagnostics, discusses COVID-19 testing with E. David Crawford, MD. Mr. Martin explains the type of tests currently used around the world, how exactly the tests are administered, and why these tests are running into problems. He goes on to discuss how his company is developing a validated sputum-based test which is more accurate and more sensitive that can be ordered directly from the company then shipped directly to the patient’s home to avoid contact as much as possible, with results available through an online portal within a week.
Testing will be available from the MicroGen website starting Monday, March 23rd.
For other urology-focused information on the COVID-19 pandemic, please see our other posts, including:
COVID-19’s Impact on the Treatment of Urology Patients
What Urologists Need to Know About COVID-19
ABOUT THE AUTHOR
Rick Martin is the CEO of MicroGen Diagnostics in Orlando, Florida. MicroGen Diagnostics specializes in next-generation DNA sequencing for the diagnosis of microbial infections, and their MicroGenDX® system of molecular diagnostics reduces the likelihood of errors in specimen collection, handling, stability, and time to analysis. Mr. Martin received his undergraduate degree from the University of Massachusetts Amherst. He then went on to work in sales and marketing for Pfizer for eight years. He has been with MicroGen Diagnostics since 2016.
